The efficacy of exercise training and nutritional supplementation in prostate cancer survivors
- Conditions
- Prostate cancer survivors treated with androgen deprivation therapyCancer - Prostate
- Registration Number
- ACTRN12614000317695
- Lead Sponsor
- Deakin University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 70
Men aged 50-85 years currently undergoing treatment for prostate cancer with androgen deprivation therapy. Treatment with androgen deprivation therapy must be planned to be continuous, pharmacological, administered for greater than three months at enrollment and expected to be administered for the duration of the intervention (52 weeks). All participants in the study must also have received approval from their local physician to participate in the study.
do not have the ability to complete surveys in the English language; any disorder known to affect bone, calcium or vitamin D metabolism (other than hypogonadism); currently receiving pharmacological intervention known to affect bone metabolism (other than androgen deprivation therapy); supplementation with protein, calcium (>600 mg/d) or vitamin D (>1000 IU/d) in the past three months; have undertaken progressive resistance training (>1 session/wk) or high impact weight bearing exercise (>150 min/wk) in the past three months; current smokers; weight greater than 159kg; have plans to travel for greater than six weeks continuously within the following 52 weeks; any absolute contraindications to exercise training according to the American College of Sports Medicine guidelines.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Femoral neck areal bone mineral density (measured via DXA)[Baseline, 26 weeks and 52 weeks.]
- Secondary Outcome Measures
Name Time Method